ArticleBMC nephrology2026
Hematologic response and kidney outcomes of monoclonal gammopathy of renal significance excluding AL amyloidosis: a report of six cases.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMonoclonal gammopathy of renal significance (MGRS) is defined as a B-cell or plasma cell clonal lymphoproliferation that produces a monoclonal immunoglobulin causing kidney lesions without leading to tumor-related complications. Although MGRS does not require hematological therapy based on tumor burden, most therapies are still carried out in accordance with hematological guidelines. AL amyloidosis is the most common form of MGRS, and substantial evidence has been accumulated regarding its treatment and response assessment. However, evidence for non-AL amyloidosis MGRS remains limited because of its rarity. This report describes six cases of non-AL amyloidosis MGRS, with the aim of contributing to the evidence base for this rare disease entity by outlining their clinical courses. CASE PRESENTATION: The six cases of non-AL amyloidosis MGRS included two with cryoglobulinemic glomerulonephritis and one each with C3 glomerulopathy, histiocytic glomerulopathy, light chain deposition disease (LCDD), and heavy chain deposition disease (HCDD). In an untreated case, one patient with C3 glomerulopathy progressed to end-stage kidney disease within 30 months of diagnosis. In contrast, patients with cryoglobulinemic glomerulonephritis, LCDD, and HCDD who received clone-directed therapy and achieved hematological complete response exhibited renal response. Of those who underwent clone-directed therapy but achieved only a hematological very good partial response, one case of cryoglobulinemic glomerulonephritis showed renal response, whereas another case of histiocytic glomerulopathy did not. In all six cases, fluctuations in the difference between involved and uninvolved free light chains (dFLC) paralleled changes in urinary protein levels, suggesting that dFLC may serve as a useful marker of disease activity. Although two of the three patients who did not achieve sufficiently reduced dFLC levels failed to obtain a renal response, all three patients who achieved greater reductions in dFLC demonstrated favorable kidney outcomes.
conclusionsThese cases underscore the importance of implementing clone-directed therapy in the management of non-AL amyloidosis MGRS and suggest that achieving lower dFLC levels may contribute to improved kidney outcomes. CLINICAL TRIAL NUMBER: Not applicable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.